The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
08. Februar 2024 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Completes Recruitment for its Landmark NEW DAY Study
24. Mai 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, May 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients
26. Juli 2022 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, July 26, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Phase 4 PALADIN Study with ILUVIEN® Published in Peer-Reviewed Journal Ophthalmology
23. Februar 2022 08:00 ET
|
Alimera Sciences, Inc.
Best corrected visual acuity and central subfield thickness were significantly improved at 36 monthsILUVIEN treatment resulted in a 70.5% reduction in treatment burdenResults confirm that use of prior...
Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands
09. Dezember 2020 08:30 ET
|
Alimera Sciences, Inc.
ATLANTA, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...
Alimera Sciences Announces Enrollment of First Patient in Landmark NEW DAY Clinical Trial to Evaluate ILUVIEN® as Baseline Therapy for Diabetic Macular Edema
01. September 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Signs Distribution Agreement With Nordic Prime to Expand International Sales of ILUVIEN® Into Nordic Countries
13. August 2020 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription...